A summary of the most watched and market-moving analyst rating changes from Wall Street is provided below. The following institutional rating adjustments, compiled by The Fly, require investors' attention today.
Five Stocks with Upgraded Ratings
Roblox Corporation (RBLX): Freedom Capital upgraded the stock from Hold to Buy, maintaining a target price of $85. The firm noted that the share price has fallen approximately 37% since early December. Beyond the attractive valuation, the outlook for fiscal year 2026 is better than expected, and there exists "significant potential for business expansion" going forward. Roku Inc (ROKU): Oppenheimer upgraded the rating from Neutral to Outperform, setting a target price of $105. The core reason for the upgrade is the current valuation advantage, influenced by the stock's 25% decline from its 52-week high. Snap Inc (SNAP): Stifel upgraded the rating from Sell to Hold, maintaining the target price of $5.50. The stock has fallen 37% year-to-date, bringing its valuation into a reasonable range, prompting the firm's rating adjustment. Estee Lauder (EL): Citigroup upgraded the rating from Neutral to Buy, keeping the target price at $120. The firm believes the stock's 19% drop following the earnings report has created an excellent buying opportunity at current levels. Boot Barn (BOOT): Stephens upgraded the rating from Equal-Weight to Overweight, raising the target price from $196 to $237. The firm commented that the company possesses a clear and market-tested model for profit growth, with a management team that is "confident, in control, and capable of accurately formulating and executing development strategies."
Five Stocks with Downgraded Ratings
Amazon.com (AMZN): DA Davidson downgraded the rating from Buy to Neutral, significantly reducing the target price from $300 to $175. Comparing performance with Microsoft and Google, the firm believes Amazon Web Services (AWS) continues to lose its industry leadership position and is currently "rushing to catch up with peers through increased investment." Sirius XM (SIRI): Seaport Research downgraded the rating from Buy to Neutral and removed its price target. Although the company's 2026 revenue and EBITDA guidance remains "stable" compared to 2025, an improvement from the negative growth guidance of prior years that has driven a corrective rally in the stock, the firm lowered its performance expectations. Reasons include a slightly larger net loss in the self-pay subscriber base for 2026 compared to 2025, expectations for slower growth in Average Revenue Per User (ARPU), and the company's allocation of most of last year's cost savings into new business initiatives. Impinj (PI): Evercore ISI downgraded the rating from Outperform to In-Line, cutting the target price from $273 to $112. The firm still views the company's long-term prospects favorably, considering it a core player in the RAIN RFID ecosystem. However, given that the company's Q3 revenue guidance came in approximately 20% below Wall Street consensus estimates, this development has completely altered the firm's valuation assessment, leading to a decision to adopt a wait-and-see stance for now. Linde PLC (LIN): JPMorgan downgraded the rating from Overweight to Neutral, maintaining the target price of $455. The primary reason for the downgrade is the stock's current price trading above the firm's target, indicating a rich valuation. Hub (HUBG): Stifel downgraded the rating directly by two notches from Buy to Sell, lowering the target price from $52 to $27. The firm informed investors that the company released partial Q4 results but has delayed the audited full report due to a material misstatement in historical profit data.
Five Stocks with New or Resumed Coverage
Merit Medical (MMSI): BTIG initiated coverage with a Buy rating and a $107 target price. The firm believes that with the rising prevalence of cardiovascular diseases, demand in the company's core end markets will remain "robust," and Merit Medical holds a solid competitive position. Sempra (SRE): JPMorgan resumed coverage following the lock-up period with an Overweight rating, raising the target price from $85 to $98. The firm stated that infrastructure demand in Texas has reached record highs, and the company is well-positioned to benefit significantly from this market opportunity, providing substantial earnings leverage. Jumia Technologies AG (JMIA): Cantor Fitzgerald initiated coverage with an Overweight rating and an $18 target price. The firm's report stated that after a "difficult" business transformation, Jumia now has the necessary conditions to potentially become the "Amazon" of the African market. JBS NV (JBS): UBS initiated coverage with a Buy rating and a $19.50 target price, implying a 23% upside from the current price. The firm anticipates that the stock will be revalued as the company lists in the U.S. and gets included in relevant U.S. indices, a process that typically unfolds over two years. NovaBridge Biosciences (NBP): H.C. Wainwright resumed coverage with a Buy rating, increasing the target price from $7 to $9. The firm indicated that the company's Givastomig monoclonal antibody drug has the potential to become a best-in-class bispecific antibody in first-line immuno-chemotherapy combination regimens.
Comments